Content area
Full text
DALLAS, Sept. 18, 2014 /PRNewswire-iReach/ -- These reports provide comprehensive information on the therapeutic development for Acute Heart Failure and Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. They also reviews key players involved in the therapeutic development and special features on late-stage and discontinued projects.
Photo - http://photos.prnewswire.com/prnh/20140918/147043
Acute Heart Failure - Pipeline Review, H1 2014- Companies Involved in Therapeutics Development: Hospira, Inc., Amgen Inc., Neurocrine Biosciences, Inc., Novartis, Bayer, Trevena, Inc., PhaseBio Pharmaceuticals, Inc., Angion Biomedica Corp., Lee's Pharmaceutical Holdings Limited and Anexon, Inc.
Chronic Heart Failure - Pipeline Review, H2 2014- Companies Involved in Therapeutics Development: Hospira, Inc., Amgen Inc., Sanofi , Novartis, Laboratoires Pierre Fabre SA, Les Laboratoires Servier SAS, Pfizer Inc., Bayer AG, Celladon Corporation, Mesoblast Limited, Palatin Technologies, Inc., AnGes MG, Inc., MetrioPharm AG, Cyano Biotech GmbH, NormOxys, Inc., Cardioxyl Pharmaceuticals, Inc. , PhaseBio Pharmaceuticals, Inc., miRagen Therapeutics, Inc., Fibrotech Therapeutics Pty. Ltd., Otsuka Holdings Co., Ltd. and Zensun (Shanghai) Sci & Tech Co., Ltd.
The reports feature investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The reports is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by research team. Drug profiles/records featured in the report undergoes periodic updation following a stringent...